World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 13 November 2023
Main ID:  NCT03808103
Date of registration: 04/01/2019
Prospective Registration: Yes
Primary sponsor: Intralytix, Inc.
Public title: Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
Scientific title: A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD)
Date of first enrolment: May 1, 2019
Target sample size: 30
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/ct2/show/NCT03808103
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).  
Phase:  Phase 1/Phase 2
Countries of recruitment
United States
Contacts
Name:     Jennifer Schwartz, PhD
Address: 
Telephone: 667-215-2597
Email: jschwartz@intralytix.com
Affiliation: 
Name:     Reezwana Chowdhury, MD
Address: 
Telephone:
Email:
Affiliation:  Johns Hopkins University
Name:     Robert Hirten, MD
Address: 
Telephone:
Email:
Affiliation:  Icahn School of Medicine at Mount Sinai
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male or female = 18 years of age

2. Inactive Crohn's disease in clinical and objective remission with a Harvey-Bradshaw
Index (HBI) < 4

3. Permitted CD medications expected to remain stable during the period of the study (see
Section 7 "Concomitant Crohn's Disease Medications" for allowed and prohibited drugs).

4. Crohn's disease history = 6-month duration

5. CRP (C-reactive protein) within normal range at the Screening visit (based on normal
range of the local laboratory)

6. Fecal calprotectin level = 150 µg/g at the Screening visit

7. AIEC detected in the stool

8. Females of childbearing age must be using an effective method of contraception to
prevent pregnancy and agree to continue to practice an acceptable method of
contraception for the duration of participation in the study (contraceptive measures
considered adequate are: intrauterine devices, hormonal contraceptives, such as
contraceptive pills, implants, transdermal patches, hormonal vaginal devices or
injections with prolonged release).

9. Negative pregnancy test for women of childbearing age (menarche to menopause)

10. Patient understands the study procedures, and can sign the informed consent, and the
authorization to release relevant protected health information to the Study
Investigator.

Exclusion Criteria:

1. Active Crohn's disease with a Harvey-Bradshaw Index (HBI) = 4

2. Ongoing gastrointestinal pathology: colorectal tumor, gastrointestinal bleeding

3. Active malignancies or any malignant disease within the past 5 years

4. Indeterminate colitis, ulcerative colitis

5. Colectomy or partial colectomy (less than ileo-transverse colonic anastomosis).

6. Colonic or small bowel stoma

7. Active perianal lesions

8. Women who are pregnant or nursing, or plan to become pregnant during the study period

9. Severe uncontrolled diseases that could increase the risk for subjects participating
in the study, including but not limited to: heart diseases, congestive heart failure,
hypertension, lung diseases; endocrine diseases; clinically significant renal disease
characterized by a glomerular filtration rate < 60mL/min, hepatic diseases,
haematological disorders, or other conditions that in the opinion of the Investigator
could interfere with the interpretation of the study results.

10. Taking supplemental probiotics in the form of pills or tablets.

11. History or planned procedures specifically aimed at modifying the gastrointestinal
microbiota within the past year.

12. Topical gastrointestinal treatment (e.g., enemas) in the 2 weeks prior to the
Screening visit or planned during the study period

13. Use of bowel cleansing or preparation for endoscopy, TDM or MRI in the 4 weeks prior
to the Screening visit or planned during the study period.

14. Receipt of antibiotics 4 weeks before the Screening visit or planned during the study
period.

15. Known allergy or hypersensitivity to an excipient in the study drug or placebo

16. Psychological or linguistic incapability to sign the informed consent.

17. Lack or expected lack of cooperation or compliance with the study.

18. Receipt of mesalamine based therapies within 4 weeks of the screening visit.

19. Severe psychiatric, psychological, or neurological disorders.

20. Alcohol, drug or medication abuse within the past year.

21. Subject who cannot be contacted in case of emergency.



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Crohn Disease
Intervention(s)
Biological: Bacteriophage preparation
Biological: Placebo
Primary Outcome(s)
Effect on Harvey Bradshaw Index (HBI) [Time Frame: Up to 6 months]
Effect on inflammation, as indicated by C-reactive protein (CRP) [Time Frame: Up to 6 months]
Incidence of adverse events [Time Frame: Up to 6 months]
Severity of adverse events [Time Frame: Up to 6 months]
Effect on inflammation, as indicated by fecal calprotectin [Time Frame: Up to 6 months]
Secondary Outcome(s)
Effect on the incidence and levels of AIEC [Time Frame: Up to 6 months]
Secondary ID(s)
ITX/EA-002
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Icahn School of Medicine at Mount Sinai
Johns Hopkins University
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history